Graphite Bio Announces Participation in Upcoming Investor Conferences
04 Mai 2022 - 2:00PM
Business Wire
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage,
next-generation gene editing company harnessing the power of
high-efficiency precision gene repair to develop therapies with the
potential to treat or cure serious diseases, today announced that
members of the management team will participate in fireside chats
at the following investor conferences:
- BofA Securities 2022 Healthcare Conference on Wednesday, May
11, 2022, at 5:40 p.m. ET;
- 2022 RBC Capital Markets Global Healthcare Conference on
Wednesday, May 18, 2022, at 11:30 a.m. ET; and
- UBS Global Healthcare Conference 2022 on Monday, May 23, 2022,
at 10 a.m. ET.
The fireside chats will be webcast live from Graphite Bio’s
website at www.graphitebio.com in the Investors section. A replay
of the webcasts will be archived and available following the
events.
About Graphite Bio Graphite Bio is a clinical-stage,
next-generation gene editing company harnessing the power of
high-efficiency precision gene repair to develop a new class of
therapies to potentially cure a wide range of serious and
life-threatening diseases. Graphite Bio is pioneering a precision
gene editing approach that could enable a variety of applications
to transform human health through its potential to achieve one of
medicine’s most elusive goals: to precisely “find & replace”
any gene in the genome. Graphite Bio’s UltraHDR™ gene editing
platform is designed to precisely correct genetic mutations,
replace entire disease-causing genes with functional genes or
insert new genes into predetermined, safe locations. The company
was co-founded by academic pioneers in the fields of gene editing
and gene therapy, including Maria Grazia Roncarolo, M.D., and
Matthew Porteus, M.D., Ph.D.
Learn more about Graphite Bio by visiting www.graphitebio.com
and following the company on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220504005173/en/
Company: Stephanie Yao VP, Communications and Investor
Relations 443-739-1423 syao@graphitebio.com
Investors: Stephanie Ascher Stern IR, Inc. 212-362-1200
ir@graphitebio.com
Media: Sheryl Seapy Real Chemistry 949-903-4750
media@graphitebio.com
Graphite Bio (NASDAQ:GRPH)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Graphite Bio (NASDAQ:GRPH)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
